Structure-based peptide inhibitors that target the Tau VQIINK fibrillization segment

US10934332B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• David S. Eisenberg · Los Angeles, US
• Paul M. Seidler · Los Angeles, US
• David Boyer · Santa Monica, US

Key dates

• Filing date: Mar 15, 2018
• Grant date: Mar 2, 2021
• Expiry date: Mar 15, 2038

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/2835
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Aggregated Tau protein is associated with over 20 neurological disorders including Alzheimer's disease. Previous work has shown that Tau's sequence segments VQIINK (SEQ ID NO: 11) and VQIVYK (SEQ ID NO: 9) drive its aggregation, and that inhibitors based on the structure of the VQIVYK (SEQ ID NO: 9) segment partially inhibit Tau aggregation. Here we show that the VQIINK (SEQ ID NO: 11) segment is the more powerful driver of Tau aggregation. Two structures of this segment determined by the cryo EM method MicroED explain its more powerful seeding. Of practical significance, the understanding of the structures has led to the design of structure based peptide inhibitors that effectively inhibit Tau aggregation as well as the ability of exogenous Tau fibrils to seed intracellular Tau in mammalian cells into amyloid.